Literature DB >> 7072839

Overview: clinical applications of the Amytal interview in psychiatric emergency settings.

J C Perry, D Jacobs.   

Abstract

The authors review the evidence for the efficacy of the sodium amytal interview with particular reference to psychiatric emergencies and rapid assessment and treatment. Amytal interviews have a valid role in the assessment and initial management of catatonia, hysterical stupor, and unexplained muteness as well as in distinguishing between depressive, schizophrenic, and organic stuporous states. Valid therapeutic indications include the abreaction of traumatic neurosis, recovery of memory in amnesic and fugue states, and recovery of function in conversion disorders. The authors offer a protocol for application of the amytal interview in emergency settings.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7072839     DOI: 10.1176/ajp.139.5.552

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  6 in total

Review 1.  Types of psychiatric treatment. Drug treatment.

Authors:  M Prendergast
Journal:  Arch Dis Child       Date:  1992-12       Impact factor: 3.791

Review 2.  The clinical use of barbiturates in neurological disorders.

Authors:  M C Smith; B J Riskin
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Acute behaviour disturbances.

Authors:  G G Lloyd
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

Review 4.  Delirium.

Authors:  D Taylor; S Lewis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-07       Impact factor: 10.154

5.  Use of Lorazepam in drug-assisted interviews: two cases of dissociative amnesia.

Authors:  Sang-Shin Lee; Sinhyung Park; Si-Sung Park
Journal:  Psychiatry Investig       Date:  2011-11-03       Impact factor: 2.505

6.  Effectiveness of lorazepam-assisted interviews in an adolescent with dissociative amnesia: A case report.

Authors:  Yuna Seo; Mi-Hee Shin; Sung-Gon Kim; Ji-Hoon Kim
Journal:  Neural Regen Res       Date:  2013-01-15       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.